Transcode Therapeutics | SC 13G:超过5%持股股东披露文件-3i, LP(9.9%),3i Management LLC(9.9%)等
Transcode Therapeutics | SC 13D:超过5%持股股东披露文件-Thomas A. Fitzgerald(5.5%)
Transcode Therapeutics | 4:持股变动声明-高管 Fitzgerald Thomas A
Transcode Therapeutics | 4:持股变动声明-董事 Manting Erik
Transcode Therapeutics | 4:持股变动声明-董事 Marquet Magda
Transcode Therapeutics | 4:持股变动声明-董事 Calais Philippe
Transcode Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Zdravka Medarova(0.4%)
Transcode Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Tang Capital Partners, LP(0.0%),Tang Capital Management, LLC(0.0%)等
Transcode Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-Lind Global Fund II LP(0.1%),Lind Global Partners II LLC(0.1%)等
Transcode Therapeutics | SC 13G:超过5%持股股东披露文件-Lind Global Fund II LP(9.9%),Lind Global Partners II LLC(9.9%)等
Transcode Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Robert Michael Dudley(1.9%)
Transcode Therapeutics | 4:持股变动声明-首席财务官 Fitzgerald Thomas A
Transcode Therapeutics | 4:持股变动声明-首席执行官 Dudley Robert Michael
Transcode Therapeutics | SC 13G:超过5%持股股东披露文件-Tang Capital Partners, LP(9.99%),Tang Capital Management, LLC(9.99%)等
Transcode Therapeutics | 4:持股变动声明-首席执行官 Dudley Robert Michael
Transcode Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Robert Michael Dudley(6.0%)
Transcode Therapeutics | 4/A:持股变动声明(修正)-首席执行官 Dudley Robert Michael
Transcode Therapeutics | 4:持股变动声明-首席执行官 Dudley Robert Michael
Transcode Therapeutics | 4:持股变动声明-董事 Manting Erik
Transcode Therapeutics | 4:持股变动声明-董事 Marquet Magda
暂无数据
暂无数据